BUFFALO, NY--(Marketwire -01/17/12)- Cleveland BioLabs, Inc. (NASDAQ: CBLI - News) today announced the online publication of a manuscript describing the radioprotective and radiomitigating properties of a new countermeasure, CBLB613, in Radiation Research (Vijay K. Singh, Elizabeth J. Ducey, Oluseyi O. Fatanmi, Pankaj K. Singh, Darren S. Brown, Andrei Purmal, Vera V. Shakhova, Andrei V. Gudkov, Elena Feinstein and Alexander Shakhov (2011) CBLB613: A TLR 2/6 Agonist, Natural Lipopeptide of Mycoplasma arginini, as a Novel Radiation Countermeasure. Radiation Research In-Press). The studies cited in the manuscript were conducted by scientists at the Armed Forces Radiobiology Research Institute and the F. Edward Hébert School of Medicine at the Uniformed Services University of the Health Sciences, Cleveland BioLabs and Roswell Park Cancer Institute.
The publication describes CBLB613, a new pharmacological agent developed by Cleveland BioLabs, which is a synthetic analogue of naturally occurring Mycoplasma derived lipopeptide ligand for Toll-like receptor 2. Participating scientists investigated CBLB613 for radioprotection, radiomitigation, toxicity, immunogenicity and pharmacokinetics in mice. CBLB613 was also evaluated for its effects on cytokine induction in unirradiated and irradiated mice, as potential mediators of the drug's action, and on radiation-induced cytopenia.
In the studies, CBLB613 mitigated radiation-induced injury and substantially increased the proportion of animals surviving lethal doses of total-body gamma-irradiation. The drug stimulated induction of a specific set of cytokines in irradiated and unirradiated mice. Furthermore, CBLB613 reduced radiation-induced cytopenia and increased the bone marrow cellularity in irradiated mice. CBLB613 was not immunogenic in mice.
Andrei Gudkov, Ph.D., D.Sc., Chief Scientific Officer of Cleveland BioLabs, and Senior Vice President of Basic Science at Roswell Park Cancer Institute, commented, "CBLB613 is our second radiation countermeasure in development following our flagship radioprotectant and radiomitigator, CBLB502, a Toll-like receptor 5 agonist. Discovery of CBLB613 reflects the power of our approach to normal tissue protection from severe stresses, such as acute radiation syndrome, that involves targeting the NF-kB pathway using natural products of human microflora. We continue to work closely with our government colleagues to characterize the physiological effects and mechanism of action of this new class of radioprotective compounds in order to define their optimal potential application and mode of use in treatment and prevention of acute radiation syndrome."
The Radiation Research publication may be found online at:
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at www.cbiolabs.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors.
These factors include, among others, the Company's history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern; the Company's need for substantial additional financing to meet its business objectives; the potential for the loss of funding from the Company's R&D grants and contracts and its ability to win additional funding under such grants and contracts; the Company's failure to successfully and timely develop new products; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company's inability to obtain regulatory approval in a timely manner or at all; the Company's collaborative relationships and the financial risks related thereto; the Company's ability to comply with its obligations under license agreements; the potential for significant product liability claims; and the Company's ability to comply with various safety, environmental and other governmental regulations. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission.
- Roswell Park Cancer Institute
Director Corporate Development & Communications
Cleveland BioLabs, Inc.
T: (646) 284-9439